Given the critical role of these cells in mediating B7-H3-induced inhibition of anti-tumor activity in ccRCC, dual targeting of B7-H3 and FOXP3+ cells may represent a promising therapeutic avenue [15]. This evidence concerns the gene FOXP3 and nonpapillary renal cell carcinoma.